Netherlands-based AM-Pharma BV has raised €116 million from a European syndicate of investors to conduct a Phase 3 trial of a drug for sepsis-associated acute kidney injury – a condition for which no pharmaceutical treatment currently exists. The financing round will enable the Dutch company to complete development of its wholly-owned product recAP as an independent company. In 2015, Pfizer Inc took out an option to acquire AM-Pharma, but last year it let the option lapse. The US company still is a minority shareholder.
